CA2360106A1 - Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies - Google Patents

Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies Download PDF

Info

Publication number
CA2360106A1
CA2360106A1 CA002360106A CA2360106A CA2360106A1 CA 2360106 A1 CA2360106 A1 CA 2360106A1 CA 002360106 A CA002360106 A CA 002360106A CA 2360106 A CA2360106 A CA 2360106A CA 2360106 A1 CA2360106 A1 CA 2360106A1
Authority
CA
Canada
Prior art keywords
tumor
alpha
beta
immunotherapeutic agent
mip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002360106A
Other languages
English (en)
Other versions
CA2360106C (fr
Inventor
Holger N. Lode
Ralph A. Reisfeld
David A. Cheresh
Stephen D. Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
EMD Serono Research and Development Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2360106A1 publication Critical patent/CA2360106A1/fr
Application granted granted Critical
Publication of CA2360106C publication Critical patent/CA2360106C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des méthodes de traitement de tumeurs simples ou métastasées chez un mammifère. Ces méthodes consistent à administrer à un mammifère atteint une dose thérapeutique d'un antagoniste suffisante pour inhiber l'angiogenèse, en combinaison avec une dose thérapeutique d'un agent immunothérapeutique anti-tumoral, par exemple une protéine de fusion cytokine/anticorps anti-antigène tumoral renfermant une cytokine et une chaîne polypeptidique d'immunoglobine recombinante suffisante pour induire une réponse biologique spécifique de la cytokine.
CA2360106A 1999-02-12 2000-02-11 Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies Expired - Fee Related CA2360106C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11972199P 1999-02-12 1999-02-12
US60/119,721 1999-02-12
PCT/US2000/003483 WO2000047228A1 (fr) 1999-02-12 2000-02-11 Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies

Publications (2)

Publication Number Publication Date
CA2360106A1 true CA2360106A1 (fr) 2000-08-17
CA2360106C CA2360106C (fr) 2012-10-30

Family

ID=22385967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2360106A Expired - Fee Related CA2360106C (fr) 1999-02-12 2000-02-11 Methodes de traitement des tumeurs et des metastases au moyen d'une combinaison de therapies anti-angiogeniques et d'immunotherapies

Country Status (22)

Country Link
US (3) US7115261B1 (fr)
EP (1) EP1156823B1 (fr)
JP (2) JP4841727B2 (fr)
KR (1) KR100704140B1 (fr)
CN (1) CN1192796C (fr)
AT (1) ATE412433T1 (fr)
AU (1) AU776790B2 (fr)
BR (1) BR0008161A (fr)
CA (1) CA2360106C (fr)
CZ (1) CZ303155B6 (fr)
DE (1) DE60040651D1 (fr)
DK (1) DK1156823T3 (fr)
ES (1) ES2313883T3 (fr)
HU (1) HU229520B1 (fr)
MX (1) MXPA01008110A (fr)
NO (2) NO331072B1 (fr)
PL (1) PL200919B1 (fr)
PT (1) PT1156823E (fr)
RU (1) RU2236251C2 (fr)
SI (1) SI1156823T1 (fr)
SK (1) SK287357B6 (fr)
WO (1) WO2000047228A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
MXPA04002575A (es) * 2001-09-20 2004-06-18 Schering Corp Quimiocinas como adyuventes de respuesta inmune.
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
GB0217017D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 2
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AU2003264378A1 (en) * 2002-09-04 2004-03-29 Proteinexpress Co., Ltd. Embryo implantation inhibitor
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
CA2544692C (fr) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican 3
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
AU2005326226B2 (en) * 2005-01-31 2010-11-11 Eci, Inc. Immunopotentiating agent
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
HUE039865T2 (hu) * 2005-12-20 2019-02-28 Sbi Biotech Co Ltd Anti-ILT7 antitest
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
WO2009086920A1 (fr) 2008-01-04 2009-07-16 Baxter International Inc. Anticorps anti-mif
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
CA2743394C (fr) * 2008-11-17 2018-01-02 Koebenhavns Universitet Peptides derives d'il-4 pour la modulation de la reponse inflammatoire chronique et le traitement de maladies auto-immunes
CA3024643C (fr) 2009-03-12 2021-08-03 Cancer Prevention And Cure, Ltd. Procedes d'identification, d'evaluation, de prevention et de therapie de maladies des poumons et leurs kits comprenant une identification, une evaluation, une prevention et une th erapie de maladies basees sur le sexe
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ES2726946T3 (es) * 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
RU2013139267A (ru) * 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2834383A1 (fr) * 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Procedes d'identification et de diagnostic de maladies pulmonaires a l'aide de systemes de classification et leurs kits
EP2714738B1 (fr) 2011-05-24 2018-10-10 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
EP2537933A1 (fr) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
BR112014003999A2 (pt) 2011-08-23 2017-06-13 Roche Glycart Ag anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
CN102634485A (zh) * 2012-03-15 2012-08-15 上海市浦东新区公利医院 一种表达il-17的胶质瘤细胞株
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
US9827309B2 (en) * 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI735410B (zh) 2014-05-08 2021-08-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投予的ｇｐｃ３標的治療劑
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US20170260285A1 (en) * 2014-11-24 2017-09-14 University Of Iowa Research Foundation Methods for treating cancer
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2017002934A1 (fr) 2015-07-01 2017-01-05 中外製薬株式会社 Agent thérapeutique à gpc3 ciblé administré à un patient dans lequel un agent thérapeutiques à gpc3 ciblé est déterminé comme étant efficace
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN106906184B (zh) * 2017-02-27 2021-04-23 广东昭泰体内生物医药科技有限公司 一种促进肺癌细胞生长的方法
KR102630070B1 (ko) * 2017-03-31 2024-01-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성인 암 줄기 세포(csc)를 표적화하여 사멸시키고 약물 내성 암을 치료하기 위한 조성물 및 방법
EP3607089A4 (fr) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC Profilage de protéine à base de plasma pour le pronostic précoce du cancer du poumon
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
CN111562362B (zh) * 2020-04-02 2022-05-20 臻悦生物科技江苏有限公司 一组用于预测三阴乳腺癌免疫联合抗血管生成治疗效果的标志物及其应用和试剂盒
CN111440244B (zh) * 2020-04-09 2021-03-16 诺未科技（北京）有限公司 靶向vegfr2的转移性癌疫苗
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262520A (en) 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CA2252584C (fr) * 1996-04-26 2008-06-10 Magainin Pharmaceuticals Inc. Traitement des carcinomes par la squalamine en association avec d'autres agents anticancereux
KR20000016301A (ko) 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물

Also Published As

Publication number Publication date
CN1192796C (zh) 2005-03-16
EP1156823A1 (fr) 2001-11-28
AU3228000A (en) 2000-08-29
AU776790B2 (en) 2004-09-23
CA2360106C (fr) 2012-10-30
WO2000047228A1 (fr) 2000-08-17
US7115261B1 (en) 2006-10-03
NO331072B1 (no) 2011-09-26
EP1156823A4 (fr) 2003-02-19
MXPA01008110A (es) 2002-10-23
ES2313883T3 (es) 2009-03-16
NO20013906L (no) 2001-10-09
PL350329A1 (en) 2002-12-02
KR20010102043A (ko) 2001-11-15
SI1156823T1 (sl) 2009-02-28
NO20013906D0 (no) 2001-08-10
CZ20012791A3 (cs) 2002-05-15
CZ303155B6 (cs) 2012-05-09
EP1156823B1 (fr) 2008-10-29
HU229520B1 (en) 2014-01-28
SK11132001A3 (sk) 2002-06-04
ATE412433T1 (de) 2008-11-15
US20070036751A1 (en) 2007-02-15
KR100704140B1 (ko) 2007-04-09
HUP0200128A2 (en) 2002-05-29
US20090060864A1 (en) 2009-03-05
JP2002536419A (ja) 2002-10-29
PT1156823E (pt) 2009-01-08
DE60040651D1 (de) 2008-12-11
PL200919B1 (pl) 2009-02-27
US7365054B2 (en) 2008-04-29
JP4841727B2 (ja) 2011-12-21
JP2011207892A (ja) 2011-10-20
US7833976B2 (en) 2010-11-16
CN1346279A (zh) 2002-04-24
NO20101696L (no) 2001-10-09
SK287357B6 (sk) 2010-08-09
RU2236251C2 (ru) 2004-09-20
DK1156823T3 (da) 2009-01-19
BR0008161A (pt) 2002-05-28

Similar Documents

Publication Publication Date Title
RU2001124907A (ru) Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US7582288B2 (en) Methods of targeting multiple cytokines
Ragnhammar et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients
JP5390055B2 (ja) 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
Gillies et al. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer
Isomäki et al. Pro-and anti-inflammatory cytokines in rheumatoid arthritis
US7365054B2 (en) Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US20050053579A1 (en) Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
Shimizu et al. Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3)
Shimamura et al. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy
EP1071469A2 (fr) Amelioration des reponses immunitaires dont la mediation est assuree par une proteine de fusion anticorps-cytokine, via coadministration de cette proteine de fusion avec un inhibiteur de prostaglandine
Paul et al. Lack of a role of interleukin 11 in the growth of multiple myeloma
Revoltella Natural and therapeutically-induced antibodies to cytokines
JP2002544172A5 (fr)
Katz et al. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy
Yamanaka et al. Effects of irradiation on cytokine production in glioma cell lines
EP1731531B1 (fr) Complexes contenant de multiples cytokines et un anticorps
Evans et al. Synergistic interaction of bacterial lipopolysaccharide and the monocyte‐macrophage colony‐stimulating factor: potential quantitative and qualitative changes in macrophage‐produced cytokine bioactivity
Huang et al. Immunotherapy of multiple myeloma
Pilson et al. Bispecific humanized anti-IL-2 receptor alpha beta antibodies inhibitory for both IL-2-and IL-15-mediated proliferation
Tsang et al. Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression
Denys et al. Increased in vitro immunosuppressive action of anti‐CMV and anti‐HBs intravenous immunoglobulins due to higher amounts of interferon‐gamma specific neutralizing antibodies
Silvennoinen et al. Growth inhibition caused by serum depletion induces differentiation, interleukin 1 receptor expression and interleukin 1 responsiveness in the HL-60 promyelocytic leukemia cell line
Kakiuchi et al. B cells as antigen-presenting cells: antigen-specific IL-2 production by cloned T cells without expression of IL-2 receptors
Banchereau Lymphokine receptor interactions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150211